Which targeted drug (bevacizumab, ramucirumab, aflibercept, or anti-EGFR?) is better for RAS-wt patients in 2nd line treatment after bevacizumab therapy?
Which targeted drug (bevacizumab, ramucirumab, aflibercept, or anti-EGFR?) is better for RAS-wt patients in 2nd line treatment after bevacizumab therapy?
Asst. Prof. Joleen Hubbard, Assoc. Prof. Yu Sunakawa
Ass. Prof. Joleen Hubbard and Ass. Prof. Yu Sunakawa discuss the Clinical Question: Which targeted drug is better for RAS-wt patients in 2nd line treatment after bevacizumab therapy?Asst. Prof. Joleen Hubbard
Medical Oncologist
Mayo Cinic Rochester
United States (US)
Asst. Prof. Joleen Hubbard has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Assoc. Prof. Yu Sunakawa
Medical Oncologist
St Marianna University
Japan
Assoc. Prof. Yu Sunakawa has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
| 5 min | 2017
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
download resources
This programme was made for you: your opinion matters
Share your feedback in just 4 clicks and help us to continue to create the content you need.
I agree that this educational programme:
Was valuable to me:
1/4
Has improved my knowledge of this topic:
2/4
Is likely to change my clinical practice:
3/4
Was balanced and unbiased:
4/4
GI CONNECT is an initiative of COR2ED, supported by an Independent Educational Grant from Bayer.